Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study

Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study

Abstract Background We evaluated a new chemoimmunotherapy combination based on the anti-PD1 monoclonal antibody pembrolizumab and the pyrimidine antimetabolite gemcitabine in HER2- advanced breast cancer (ABC) patients previously treated in the advanced setting, in order to explore a potential syner...

Full description

Bibliographic Details
Main Authors: L. de la Cruz-Merino, M. Gion, J. Cruz, JL. Alonso-Romero, V. Quiroga, F. Moreno, R. Andrés, M. Santisteban, M. Ramos, E. Holgado, J. Cortés, E. López-Miranda, A. Cortés, F. Henao, N. Palazón-Carrión, L. M. Rodriguez, I. Ceballos, A. Soto, A. Puertes, M. Casas, S. Benito, M. Chiesa, S. Bezares, R. Caballero, C. Jiménez-Cortegana, V. Sánchez-Margalet, F. Rojo
Format: Article
Language:English
Published: BMC 2022-12-01
Series:BMC Cancer
Subjects:
Pembrolizumab
Chemotherapy
HER2-negative
Advanced breast cancer
TILs
PD-L1
Online Access:https://doi.org/10.1186/s12885-022-10363-3

Internet

https://doi.org/10.1186/s12885-022-10363-3

Similar Items